Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05655910
Other study ID # AAAT9591
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 22, 2022
Est. completion date December 31, 2024

Study information

Verified date November 2022
Source Columbia University
Contact Melana Yuzefpolskaya, MD
Phone 3472681454
Email my2249@cumc.columbia.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to assess whether a peri-operative intervention with nutritional immune modulating intervention (Ensure Surgery Immunonutrition shake) has beneficial effects on the complex interplay between gut microbiome, systemic inflammation and malnutrition that is commonly present in advanced heart failure and the adverse events associated with left ventricular assist device (LVAD) placement in hospitalized advanced heart failure patients awaiting LVAD implantation. The main questions it aims to answer are: - Will pre-surgical supplementation with Ensure Surgery affect gut microbial composition and levels of inflammation among heart failure patients undergoing LVAD implantation? - Will pre-surgical supplementation with Ensure Surgery affect post-surgical morbidity (e.g., infections, intensive care unit length of stay (LOS)) and mortality? Participants will be evaluated for malnutrition and will be given Ensure Surgery Immunonutrition shake to drink in the days preceding their LVAD surgery. Blood and stool samples will be collected at prespecified timepoints before and after surgery. Researchers will compare malnourished participants drinking Ensure Surgery 3/day with well-nourished participants randomized to drink either 1/day or 3/day to see if any of the above supplementation strategies change the gut microbial composition, levels of inflammation, and post-surgical morbidity and mortality.


Description:

Heart failure (HF) has an estimated prevalence of >37.7 million individuals globally. In the US alone, which is projected to increase by 46% between the years 2012 and 2030. Despite significant advances in HF medical and device therapies, patient prognosis after their first HF hospital admission is poor, with a <50% survival rate at five years and significant proportion of patients progressing from chronic stable disease to advanced HF state. Once advanced HF ensues, LVADs are one of the two main treatment modalities that can meaningfully improve survival in this patient population. Chronic systemic inflammation is commonly observed in HF and is believed to be directly related to its pathogenesis. Recently, perturbations in the gut microbiota known as "gut dysbiosis" and impairment of gut mucosal barriers, facilitating entry of endotoxins and gut metabolites into the circulation, have also been observed in HF patients. Elevated levels of circulating endotoxins and bacterial bi-products enhance systemic inflammation, thereby contributing to progression of HF to more advanced disease state. Gut microbial perturbations may also alter enterocyte structure and function resulting in gastrointestinal dysmotility, nutrient malabsorption and eventually malnutrition. Malnutrition is frequent in HF (as high as 62%), is associated with higher rates of mortality, hospital readmissions and an increased risk of adverse early postoperative outcomes. Infections are the most common complications following LVAD, affecting >50% of HF patients, contributing significantly to postoperative mortality, increased length-of stay (LOS) and hospital readmissions. The pre-operative period may represent an attractive time window in which to optimize HF patients, correct deficiencies, and enhance immune defense mechanisms before surgery. This period allows to act upon modifiable risk factors, such as the nutritional status, and potentially lower the risk of postoperative complications. However, the literature on perioperative optimization in HF comes mainly from anesthesiology and focuses on intra- and immediate postoperative management, when it may be too late to intervene and alter the outcome. Interestingly, guidelines on the nutritional evaluation and management of patients prior to non-cardiac surgery are available, but very limited literature is published concerning cardiac surgery, and no data exists with respect to LVAD surgery. The investigators plan to evaluation of the impact of preoperative nutrition intervention.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date December 31, 2024
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - age >18 years - hospitalized - undergoing LVAD therapy (enrolled at time of acceptance) Exclusion Criteria: - intubated - congenital heart disease - infiltrative cardiomyopathy - unable to tolerate oral nutrition - surgery expected in <5 days

Study Design


Intervention

Dietary Supplement:
Ensure Surgery Immunonutrition shake
Nutrition shake to support immune health and recovery from surgery.

Locations

Country Name City State
United States Columbia University Medical Center New York New York

Sponsors (2)

Lead Sponsor Collaborator
Columbia University Abbott Nutrition

Country where clinical trial is conducted

United States, 

References & Publications (15)

Al-Najjar Y, Clark AL. Predicting outcome in patients with left ventricular systolic chronic heart failure using a nutritional risk index. Am J Cardiol. 2012 May 1;109(9):1315-20. doi: 10.1016/j.amjcard.2011.12.026. Epub 2012 Feb 13. — View Citation

Engelman DT, Ben Ali W, Williams JB, Perrault LP, Reddy VS, Arora RC, Roselli EE, Khoynezhad A, Gerdisch M, Levy JH, Lobdell K, Fletcher N, Kirsch M, Nelson G, Engelman RM, Gregory AJ, Boyle EM. Guidelines for Perioperative Care in Cardiac Surgery: Enhanced Recovery After Surgery Society Recommendations. JAMA Surg. 2019 Aug 1;154(8):755-766. doi: 10.1001/jamasurg.2019.1153. — View Citation

Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990 Nov;82(5):1724-9. doi: 10.1161/01.cir.82.5.1724. — View Citation

Gustafsson UO, Scott MJ, Schwenk W, Demartines N, Roulin D, Francis N, McNaught CE, MacFie J, Liberman AS, Soop M, Hill A, Kennedy RH, Lobo DN, Fearon K, Ljungqvist O; Enhanced Recovery After Surgery Society. Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS(R)) Society recommendations. Clin Nutr. 2012 Dec;31(6):783-800. doi: 10.1016/j.clnu.2012.08.013. Epub 2012 Sep 28. — View Citation

Kummen M, Mayerhofer CCK, Vestad B, Broch K, Awoyemi A, Storm-Larsen C, Ueland T, Yndestad A, Hov JR, Troseid M. Gut Microbiota Signature in Heart Failure Defined From Profiling of 2 Independent Cohorts. J Am Coll Cardiol. 2018 Mar 13;71(10):1184-1186. doi: 10.1016/j.jacc.2017.12.057. No abstract available. — View Citation

Lin H, Zhang H, Lin Z, Li X, Kong X, Sun G. Review of nutritional screening and assessment tools and clinical outcomes in heart failure. Heart Fail Rev. 2016 Sep;21(5):549-65. doi: 10.1007/s10741-016-9540-0. — View Citation

Luedde M, Winkler T, Heinsen FA, Ruhlemann MC, Spehlmann ME, Bajrovic A, Lieb W, Franke A, Ott SJ, Frey N. Heart failure is associated with depletion of core intestinal microbiota. ESC Heart Fail. 2017 Aug;4(3):282-290. doi: 10.1002/ehf2.12155. Epub 2017 Apr 21. — View Citation

Munger MA, Johnson B, Amber IJ, Callahan KS, Gilbert EM. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1996 Apr 1;77(9):723-7. doi: 10.1016/s0002-9149(97)89206-5. — View Citation

Roger VL. Epidemiology of heart failure. Circ Res. 2013 Aug 30;113(6):646-59. doi: 10.1161/CIRCRESAHA.113.300268. — View Citation

Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber-Eibel J, von Haehling S, Schroedl W, Karhausen T, Doehner W, Rauchhaus M, Poole-Wilson P, Volk HD, Lochs H, Anker SD. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol. 2007 Oct 16;50(16):1561-9. doi: 10.1016/j.jacc.2007.07.016. Epub 2007 Oct 1. — View Citation

Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017 Apr;3(1):7-11. doi: 10.15420/cfr.2016:25:2. — View Citation

Schorghuber M, Fruhwald S. Effects of enteral nutrition on gastrointestinal function in patients who are critically ill. Lancet Gastroenterol Hepatol. 2018 Apr;3(4):281-287. doi: 10.1016/S2468-1253(18)30036-0. Epub 2018 Mar 7. — View Citation

Sze S, Zhang J, Pellicori P, Morgan D, Hoye A, Clark AL. Prognostic value of simple frailty and malnutrition screening tools in patients with acute heart failure due to left ventricular systolic dysfunction. Clin Res Cardiol. 2017 Jul;106(7):533-541. doi: 10.1007/s00392-017-1082-5. Epub 2017 Feb 15. — View Citation

Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman JW, LeJemtel TH. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol. 1996 Oct;28(4):964-71. doi: 10.1016/s0735-1097(96)00268-9. — View Citation

Yuzefpolskaya M, Bohn B, Nasiri M, Zuver AM, Onat DD, Royzman EA, Nwokocha J, Mabasa M, Pinsino A, Brunjes D, Gaudig A, Clemons A, Trinh P, Stump S, Giddins MJ, Topkara VK, Garan AR, Takeda K, Takayama H, Naka Y, Farr MA, Nandakumar R, Uhlemann AC, Colombo PC, Demmer RT. Gut microbiota, endotoxemia, inflammation, and oxidative stress in patients with heart failure, left ventricular assist device, and transplant. J Heart Lung Transplant. 2020 Sep;39(9):880-890. doi: 10.1016/j.healun.2020.02.004. Epub 2020 Feb 13. — View Citation

* Note: There are 15 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Alpha Diversity (Baseline and Day 5) Change in alpha diversity (a measure of microbiome diversity applicable to a single sample) in collected stool samples. Baseline and Day 5
Primary Change in Alpha Diversity (Baseline and Pre-VAD) Change in alpha diversity (a measure of microbiome diversity applicable to a single sample) in collected stool samples. Baseline and Pre-VAD (approximately Day 0-5)
Primary Change in Alpha Diversity (Baseline and Discharge) Change in alpha diversity (a measure of microbiome diversity applicable to a single sample) in collected stool samples. Baseline and Discharge (approximately Day 25)
Primary Change in Alpha Diversity (Baseline and Post-Discharge Follow-up) Change in alpha diversity (a measure of microbiome diversity applicable to a single sample) in collected stool samples. Baseline and Post-Discharge Follow-up (approximately Day 55)
Primary Change in Microbial Gene Count (Baseline and Day 5) Change in microbial gene count as measured in stool samples. Baseline and Day 5
Primary Change in Microbial Gene Count (Baseline and Pre-VAD) Change in microbial gene count as measured in stool samples. Baseline and Pre-VAD (approximately Day 0-5)
Primary Change in Microbial Gene Count (Baseline and Discharge) Change in microbial gene count as measured in stool samples. Baseline and Discharge (approximately Day 25)
Primary Change in Microbial Gene Count (Baseline and Post-Discharge Follow-up) Change in microbial gene count as measured in stool samples. Baseline and Post-Discharge Follow-up (approximately Day 55)
Primary Change in C-Reactive Protein (CRP) (Baseline and Day 5) Change in biomarker CRP as measured in blood samples. Baseline and Day 5
Primary Change in C-Reactive Protein (CRP) (Baseline and Pre-VAD) Change in biomarker CRP as measured in blood samples. Baseline and Pre-VAD (approximately Day 0-5)
Primary Change in C-Reactive Protein (CRP) (Baseline and Discharge) Change in biomarker CRP as measured in blood samples. Baseline and Discharge (approximately Day 25)
Primary Change in C-Reactive Protein (CRP) (Baseline and Post-Discharge Follow-up) Change in biomarker CRP as measured in blood samples. Baseline and Post-Discharge Follow-up (approximately Day 55)
Primary Change in N-terminal (NT)-pro hormone BNP (NT-proBNP) (Baseline and Day 5) Change in biomarker NT-proBNP as measured in blood samples. Baseline and Day 5
Primary Change in N-terminal (NT)-pro hormone BNP (NT-proBNP) (Baseline and Pre-VAD) Change in biomarker NT-proBNP as measured in blood samples. Baseline and Pre-VAD (approximately Day 0-5)
Primary Change in N-terminal (NT)-pro hormone BNP (NT-proBNP) (Baseline and Discharge) Change in biomarker NT-proBNP as measured in blood samples. Baseline and Discharge (approximately Day 25)
Primary Change in N-terminal (NT)-pro hormone BNP (NT-proBNP) (Baseline and Post-Discharge Follow-up) Change in biomarker NT-proBNP as measured in blood samples. Baseline and Post-Discharge Follow-up (approximately Day 55)
Primary Change in lipopolysaccharide (LPS) (Baseline and Day 5) Change in biomarker LPS as measured in blood samples. Baseline and Day 5
Primary Change in lipopolysaccharide (LPS) (Baseline and Pre-VAD) Change in biomarker LPS as measured in blood samples. Baseline and Pre-VAD (approximately Day 0-5)
Primary Change in lipopolysaccharide (LPS) (Baseline and Discharge) Change in biomarker LPS as measured in blood samples. Baseline and Discharge (approximately Day 25)
Primary Change in lipopolysaccharide (LPS) (Baseline and Post-Discharge Follow-up) Change in biomarker LPS as measured in blood samples. Baseline and Post-Discharge Follow-up (approximately Day 55)
Primary Change in Tumor Necrosis Factor (TNF) (Baseline and Day 5) Change in biomarker TNF as measured in blood samples. Baseline and Day 5
Primary Change in Tumor Necrosis Factor (TNF) (Baseline and Pre-VAD) Change in biomarker TNF as measured in blood samples. Baseline and Pre-VAD (approximately Day 0-5)
Primary Change in Tumor Necrosis Factor (TNF) (Baseline and Discharge) Change in biomarker TNF as measured in blood samples. Baseline and Discharge (approximately Day 25)
Primary Change in Tumor Necrosis Factor (TNF) (Baseline and Post-Discharge Follow-up) Change in biomarker TNF as measured in blood samples. Baseline and Post-Discharge Follow-up (approximately Day 55)
Primary Change in Interleukin 6 (IL-6) (Baseline and Day 5) Change in biomarker IL-6 as measured in blood samples. Baseline and Day 5
Primary Change in Interleukin 6 (IL-6) (Baseline and Pre-VAD) Change in biomarker IL-6 as measured in blood samples. Baseline and Pre-VAD (approximately Day 0-5)
Primary Change in Interleukin 6 (IL-6) (Baseline and Discharge) Change in biomarker IL-6 as measured in blood samples. Baseline and Discharge (approximately Day 25)
Primary Change in Interleukin 6 (IL-6) (Baseline and Post-Discharge Follow-up) Change in biomarker IL-6 as measured in blood samples. Baseline and Post-Discharge Follow-up (approximately Day 55)
Primary Change in Interleukin 10 (IL-10) (Baseline and Day 5) Change in biomarker IL-10 as measured in blood samples. Baseline and Day 5
Primary Change in Interleukin 10 (IL-10) (Baseline and Pre-VAD) Change in biomarker IL-10 as measured in blood samples. Baseline and Pre-VAD (approximately Day 0-5)
Primary Change in Interleukin 10 (IL-10) (Baseline and Discharge) Change in biomarker IL-10 as measured in blood samples. Baseline and Discharge (approximately Day 25)
Primary Change in Interleukin 10 (IL-10) (Baseline and Post-Discharge Follow-up) Change in biomarker IL-10 as measured in blood samples. Baseline and Post-Discharge Follow-up (approximately Day 55)
Primary Change in Short-Chain Fatty Acids (Baseline and Day 5) Change in short-chain fatty acids as measured in blood samples. Baseline and Day 5
Primary Change in Short-Chain Fatty Acids (Baseline and Pre-VAD) Change in short-chain fatty acids as measured in blood samples. Baseline and Pre-VAD (approximately Day 0-5)
Primary Change in Short-Chain Fatty Acids (Baseline and Discharge) Change in short-chain fatty acids as measured in blood samples. Baseline and Discharge (approximately Day 25)
Primary Change in Short-Chain Fatty Acids (Baseline and Post-Discharge Follow-up) Change in short-chain fatty acids as measured in blood samples. Baseline and Post-Discharge Follow-up (approximately Day 55)
Secondary Post-LVAD Infections Number and type of infections experienced during index hospitalization following LVAD implantation Day 25
Secondary Post-LVAD Length of Stay in intensive care unit Number of days spent in intensive care unit following LVAD implantation. Day 25
Secondary Post-LVAD Mortality Number of participant deaths. Up to 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05654272 - Development of CIRC Technologies
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy